Australian Particle Therapy Clinical Quality Registry


Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long-term toxicities of photon and proton radiation therapy.

For more about ASPIRE visit: https://www.protontherapy.sahmri.org.au/about-aptcqr/

Primary Sponsor

South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research)

Collaborating Groups

TROG Cancer Research

Trial Chairperson

A/Prof Hien Le, Royal Adelaide Hospital, SA

Trial Contact

ASPIRE@sahmri.com

Clinical Trial Registration

Related Post

Yu Yang Soon, TROG Lung Working Party
31 July, 2025

World Lung Cancer Day: Focus on the TROG Lung Working Party

TROG WORKING PARTY IN FOCUS: 31 July 2025 To

29 July, 2025

TROG 21.07 SOCRATES HCC Trial Expands Outreach

TRIAL IN FOCUS: 29 July 2025 We’ve extended the